ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1763

The Role of SYK in Human B CELL Activation and Its Relevance to Autoimmune Diseases

Shigeru Iwata1, Kunihiro Yamaoka1, Hiroaki Niiro2, Kazuhisa Nakano1, Sheau-Pey Wang1, Koichi Akashi2 and Yoshiya Tanaka1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, 2Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Fukuoka, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: B cells play a pivotal role in pathological processes of autoimmune diseases. Spleen tyrosine kinase (Syk) functions as a key molecule in B-cell receptor (BCR)-mediated signaling. However, the underlying mechanisms of Syk in autoimmune diseases such as RA and SLE remain unclear.

Methods: Purified naïve (CD27–) and memory (CD27–) B cells from healthy donor were stimulated with BCR cross-linking, soluble CD40L, and CpG-ODN2006. The role of Syk was evaluated with a specific Syk inhibitor: BAY61-3606. B cell line (Raji) and PBMCs from RA and SLE patients were utilized to assess the detailed molecular mechanism of activated B cells and involvement in the pathology of RA and SLE.

Results: BCR-crosslinking, in conjunction with CD40 and TLR-9 stimulations, efficiently activate B cells and induced various functions such as proliferation and differentiation especially in memory B cells, while specific Syk inhibitors completely abrogated them to background levels. It is noteworthy that BCR-crosslinking markedly induced expression of TNF receptor-associated factor (TRAF)-6 but not TRAF-2,-3 and -5. Additional CD40 and TLR9 stimulations further induced expression of TRAF-6 and phosphorylation of NF-κB, while a Syk inhibitor again significantly inhibited them. Strong phosphorylation of Syk were observed in B cells from RA (n=62) and SLE patients(n=58) compared with healthy donors (n=27). Levels of Syk phosphorylation were higher in SLE patients positive for anti-dsDNA antibodies than those negative for them and also well correlated with the disease activity score such as SLEDAI. On the other hand, Syk phosphorylation were higher in RA patients most positive for anti-CCP antibodies than those negative for them, however, not correlated with the disease activity score such as DAS28, CDAI and SDAI.

Conclusion: Syk-mediated BCR-signaling is prerequisite for optimal induction of TRAF-6, thereby allowing efficient propagation of TLR9-signaling critical for proliferation and differentiation of human memory B cells. Moreover, we suggest that Syk-mediated signaling on B cells is involved in pathological process in autoimmune diseases via producing autoantibody, however, more dominantly in pathology of SLE compared with RA.


Disclosure:

S. Iwata,
None;

K. Yamaoka,
None;

H. Niiro,
None;

K. Nakano,
None;

S. P. Wang,
None;

K. Akashi,
None;

Y. Tanaka,

Dr. Tanaka has received consulting fees, speaking fees, and/or honoraria ,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-syk-in-human-b-cell-activation-and-its-relevance-to-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology